29. THE PREVALENCE OF LIVER FIBROSIS AND EFFECTIVENESS OF KNOWLEDGE AND PRACTICE INTERVENTIONS IN MIDDLE–AGED MALE ALCOHOL USERS
Main Article Content
Abstract
Objective: (1) To determine the prevalence of liver fibrosis in middle–aged men who consume alcohol; (2) To assess the effectiveness of knowledge and practice interventions in improving liver fibrosis in middle–aged male alcohol users.
Subject and method: A cross–sectional descriptive study with an uncontrolled intervention was conducted on 513 middle–aged male alcohol users who came Military Hospital 121 for a routine health check-up from April 2022 to March 2023.
Results: The prevalence of liver fibrosis was 29.3%. After the intervention, the rate of achieving general knowledge increased from 18.4% to 82.3%, achieving general practice increased from 4.8% to 98.6%, and achieving both knowledge and practice increased from 0.0% to 81.6%. The prevalence of liver fibrosis decreased to 73.5%, with a statistically significant difference (p<0.001). Initial liver fibrosis stage ≥ F2 and failure to achieve both knowledge and practice post–intervention were associated with no improvement in liver fibrosis stage.
Conclusion: The prevalence of liver fibrosis was nearly one–third among middle–aged male alcohol users. Knowledge and practice interventions during examination and treatment adherence partially improved liver fibrosis; however, the effectiveness was limited in patients with fibrosis stage F2 and above.
Article Details
Keywords
liver fibrosis, middle-aged men, alcohol consumption, knowledge and practice interventions
References
[2] Trifan A, Muzica CM, Nastasa R. et al. High prevalence of liver fibrosis among general population: a Romanian population-based study. Hepatology communications, 2023, 7(2): e0032.
[3] Lee JS. Alcohol Consumption and Quality of Life in Middle-aged Men. International Journal of High Risk Behaviors and Addiction, 2023, 12(1): e132404.
[4] AlKalbani SR, Murrin C. The association between alcohol intake and obesity in a sample of the Irish adult population, a cross-sectional study. BMC Public Health, 2023, 23: 2075.
[5] Yang S, Cheng J, Zhang R et al. Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population. Hepatology Research, 2022, 52(2): 176-186.
[6] Nah E, Cho S, Kim S et al. Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study, BMJ Open, 2021, 11: e046529.
[7] Kjaergaard M, Lindvig KP, Thorhauge KH et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clinical Gastroenterology and Hepatology, 2024, 22(5): 1037-1047.
[8] Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. The Korean journal of internal medicine, 2017, 32(2): 213–228.
[9] Jielin L, Jiexuan H, Peng L et al. Analysis of risk factors associated with endoscopic retrograde cholangiopancreatography for patients with liver cirrhosis: a multicenter, retrospective, clinical study. Chinese Medical Journal, 2022, 135(19): 2319-2325.
[10] Elsharkawy A, Samir R, El-Kassas M. Fibrosis regression following hepatitis C antiviral therapy. World journal of hepatology, 2022, 14(6): 1120–1130.